(MDT:New York Consolidated)
Transactions by MEDTRONIC INC (MDT) in the last 6 months
Integra LifeSciences Corporation entered into a stock and asset purchase agreement to acquire Medtronic Xomed Instrumentation SAS and certain assets of Medtronic, Inc. (NYSE:MDT) for approximately $60 million in cash on September 12, 2014. The consideration is subject to a purchase price adjustment for certain working capital changes. Integra plans to fund this transaction with cash held outside the U.S. The purchase agreement contains certain termination rights allowing ...
Cleveland Imaging and Surgical Hospital, L.L.C. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on September 4, 2014. The debtor listed its assets of $12.08 million and liabilities of $18.74 million. The largest unsecured creditors include Aetna Life Insurance Company, Inc., Prexus Health, LLC, Texas Emergency Room Services, P. A., Vee Technologies USA, Texas Lithotripsy L P Viii, Medtronic, ...
Innovative X Ray Services LLC
Prexus Health, LLC
Siemens Financial Services, Inc.
Texas Emergency Room Services, P. A.
Texas Lithotripsy L P Viii
Vee Technologies USA
Acufocus, Inc. announced that it will raise $15,695,083 in a round of funding on August 29, 2014. The company will issue common stock pursuant to exemption provided under Regulation D.
HealthCare Royalty Partners
SV Life Sciences Advisers, LLC
The Carlyle Group LP
Versant Ventures, Inc.
Medtronic, Inc. (NYSE:MDT) acquired the remaining 70% stake in N.G.C. Medical S.p.A. for approximately $240 million on August 26, 2014. Post acquisition, NGC will operate as a separate entity and will serve as the Managed Services arm for Medtronic's Hospital Solutions business. Medtronic expects the net impact from this transaction to be neutral to fiscal year 2015 earnings. Paola Sangiovanni of Italy Legal Focus acted aas legal advisor for Medtronic. Luigi Croce of ...
Medtronic, Inc. (NYSE:MDT) acquired Sapiens Steering Brain Stimulation from BioDiscovery 3, FCPR managed by Edmond de Rothschild Investment Partners, S.A.S., Life Sciences Partners BV, INKEF Capital, Wellington Ventures, Wellcome Trust, Investment Division and Gilde Healthcare III managed by Gilde Healthcare Partners B.V. for approximately $200 million in cash on August 25, 2014. The group of sellers includes Wellington Ventures, Wellcome Trust, Investment Division, ...
Edmond de Rothschild Investment Partners, S.A.S.
Gilde Healthcare III
Gilde Healthcare Partners B.V.
Life Sciences Partners BV
NeuroNexus Technologies, Inc.
Wellcome Trust, Investment Division
Intrinsic Therapeutics, Inc. announced that it will receive $20,878,287 in an equity round of funding on August 22, 2014. The company will issue the securities pursuant to exemption provided under Regulation D.
As of September 17, 2014, the company has received $17,256,239 from 28 investors. The transaction included participation from existing investors New Enterprise Associates, Quilvest Private Equity Ltd., and New Leaf Venture Partners. Medtronic, Inc. and Greenspring ...
New Enterprise Associates
New Leaf Venture Partners
Quilvest Private Equity Ltd.
Medtronic, Inc. (NYSE:MDT) acquired 91.43% stake in Visualase, Inc. for $99 million from Eventi Capital Partners on July 28, 2014. The transaction includes an initial payment of $64 million plus additional payments of up to $35 million which are contingent upon Visualase achievement of specific milestones. Medtronic expects the net impact from the transaction to be neutral to fiscal year 2015 earnings and accretive thereafter. Leerink Partners LLC acted as the financial ...
|Allergan Inc/United States||$208.03 USD||+2.28|
|Astellas Pharma Inc||¥1,655 JPY||+1.50|
|Becton Dickinson and Co||$136.80 USD||+2.76|
|Fresenius SE & Co KGaA||€42.04 EUR||-0.038|
|Stryker Corp||$92.83 USD||+2.05|
|View Industry Companies|